VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ...

The FDA declined to approve tradipitant for adults with symptoms of gastroparesis, or delayed gastric emptying, drugmaker ...

Even more concerning is Vanda’s failure to receive FDA clearance for tradipitant, whose prospects had been prominently cited in June by Vanda for its rejection of our initial offer. The ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...

The Food and Drug Administration has turned away a proposed drug from Vanda Pharmaceuticals to treat the stomach disorder gastroparesis. Vanda on Thursday said the FDA has issued a so-called ...

Even more concerning is Vanda’s failure to receive FDA clearance for tradipitant, whose prospects had been prominently cited in June by Vanda for its rejection of our initial offer. The ...

Cycle is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda Board’s continued refusal to engage following the receipt of multiple premium proposals, Vanda’s ...

The US Food and Drug Administration (FDA) has declined to approve the new drug application (NDA) submitted by Vanda Pharmaceuticals for tradipitant to treat gastroparesis symptoms. The decision ...

Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "On the research and development front, we are focused on completing in the coming months our New Drug Applications for ...

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and ...

Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is ...